On October 10, Sansure Biotech Inc. won the Medical Innovation Award in the G20 Innovation Alliance Forum held in Sorrento, Italy, making it the only Chinese company receiving this honor. This first ever event in the history of G20 was hosted by the rotating presidency Italy this time, and it was dedicated to sharing ideas and innovative solutions in response […]

According to the agreement, Sansure will work closely with PowerChina International against the backdrop of the grim and complex COVID-19 outbreak overseas. The two parties will exchange experience, resources and reference cases, actively explore and enhance technical support for nucleic acid testing equipment, customer service and joint promotion. This cooperation will help ensure equipment availability and bio-safety, and strengthen protection […]

On August 1st, the much-anticipated Top 100 Pharmaceutical Enterprises in China for 2020 was officially released at the 38th China Pharmaceutical Industry Information Annual Conference 2021, which was organized by the China National Pharmaceutical Industry Information Center. Sinopharm, Yangtze River Pharmaceutical Group and Guangzhou Pharmaceutical Holdings were ranked top three while Sansure Biotech, ranked 59th, is the only biomedical company […]

Sansure Statement on the effectiveness of nucleic acid test kits for the SARS-CoV-2 variants detection

Recently, the Detection Kit for 5 Mutations of SARS-CoV-2 (PCR-Fluorescence Probing) developed by Sansure Biotech have obtained the European Union CE certification. This is another COVID-19 mutations diagnostic product which obtained the EU CE certification after the mutations diagnostic kit for the identification of B.1.1.7 major mutation sites N501Y and HV69-70 del obtained the CE certification. This product can simultaneously […]